Explore the Agenda

Day One

Wednesday, August 5

Day Two

Thursday, August 6

8:15 am Check-in, Coffee & Networking

9:00 am Chair’s Opening Remarks

Executive Vice President, General Counsel, Parabilis Medicines

Deploying Responsible AI to Amplify Legal Capacity & Strengthen Enterprise Oversight

9:15 am Accelerating FDA Submissions Through AI-Assisted Module Drafting to Reduce Risk & Enhance Regulatory Efficiency

General Counsel & Corporate Secretary , Enveda Therapeutics, Inc.
  • Shortening submission timelines and expanding legal and regulatory capacity by embedding AI into FDA module drafting for a live Phase 2 asset
  • Mitigating hallucination, confidentiality, and trade-secret exposure through structured guardrails, validation workflows, and disciplined human oversight
  • Demonstrating measurable ROI through a real-world implementation with an external AI partner while preserving defensibility and data integrity

9:45 am Roundtable Discussion: Operationalizing Enterprise AI to Enhance Legal Capacity & Preserve Budget Discipline

  • Replacing fragmented individual AI usage with enterprise-wide platforms, structured guardrails, and company-wide training to reduce confidentiality and compliance risk
  • Integrating AI into contract management and routine legal workflows to handle more work internally and reduce reliance on outside counsel
  • Securing executive alignment by framing AI investment through disciplined budget comparisons and realistic year-one performance expectations

10:15 am Morning Break & Networking

Optimizing IP & Trade Secrets to Strengthen Competitive Positioning, Deal Leverage & LongTerm Defensibility

10:45 am Panel Discussion: Ensuring Cross-Functional Alignment to Safeguard IP Defensibility & Preserve Enterprise Value

General Counsel & Corporate Secretary , Enveda Therapeutics, Inc.
Head of Intellectual Property, Crescent Biopharma
Principal & Fractional CSO, Gene Editing Frontiers
SVP, Legal & Alliance Management (Head of IP), Mammoth Biosciences
  • Strengthening collaboration between scientific, regulatory and legal teams to support robust patent scope and resilient trade-secret protection
  • Coordinating disclosure timing, data generation, and regulatory positioning to strengthen valuation, diligence readiness, and lifecycle strategy
  • Reducing downstream enforcement, inventorship, and documentation risk in an increasingly AI-enabled R&D environment

11:30 am Fireside Chat: Aligning IP Strategy to Protect Assets and Strengthen Deal Leverage

Vice President Head of Intellectual Property, Generate Biomedicines, Inc
  • Build a deal-ready IP position by aligning exclusivity, data generation, and disclosure timing with partner expectations
  • Avoid deal blockers by addressing ownership, platform boundaries, and other IP issues that commonly surface during negotiations
  • Strengthen leverage with a clear IP narrative that distinguishes asset IP from platform IP and supports confident decision-making

12:00 pm Networking Lunch

Managing Geopolitical & Cross-Border Complexity to Maintain Operational Continuity

1:00 pm Fireside Chat: Structuring Biotech Collaborations for Value, Control and Longevity

General Counsel & Corporate Secretary, Arbor Biotechnologies, Inc.
  • Current negotiation trends in licensing and collaboration deals with big pharma and peer biotechs in competitive global markets
  • Strategies for protecting platform IP and downstream inventions in collaborations
  • Governance frameworks supporting long-term alliances to maximize control and maintain strategic focus

1:30 pm Panel Discussion: Anticipating Geopolitical & Trade Policy Shifts to Preserve Cross-Border Operational Continuity

General Counsel, Legend Biotech
  • Reduce enterprise disruption by tracking geopolitical shifts affecting trade access, regulatory cooperation, and BIOSECURE-driven supply-chain exposure
  • Protect international growth by aligning global footprint and manufacturing strategy with export controls, industrial policy, and supply-continuity risks
  • Strengthen board readiness with scenarios that maintain stability amid tariff escalation and policy shocks

2:00 pm Afternoon Networking Break

2:29 pm Elevating GC Leadership to Strengthen Cross-Functional Alignment & Executive Impact

2:30 pm Fireside Chat: Influencing the Board During Volatility to Strengthen Strategic Judgment

Chief Legal Officer, Caribou Biosciences, Inc.
  • Deliver decision-ready counsel during regulatory, pricing, or capital-market uncertainty
  • Shape board-level debate by framing risk trade-offs with clarity and commercial awareness
  • Build long-term credibility through disciplined, forward-looking governance leadership

3:00 pm Roundtable Discussions: Embedding Legal Leadership to Accelerate Cross-Functional Execution

Formerly General Counsel & Head of Compliance, Corstasis Therapeutics
Chief Legal Officer & Corporate Secretary, Olema Oncology
Executive Vice President, General Counsel, Parabilis Medicines

3:45 pm Fireside Chat: Developing the Next Generation of GC Leadership to Strengthen Succession & Enterprise Resilience

General Counsel & Corporate Secretary, Arbor Biotechnologies, Inc.
Chief Legal Officer, Indivior Plc.
Executive Vice President, General Counsel, Parabilis Medicines
  • Build internal talent pipelines by intentionally developing senior counsel for broader enterprise leadership
  • Equip high-performing in-house lawyers with the judgment, cross-functional fluency, and board exposure required for GC readiness
  • Strengthen organizational stability through deliberate succession planning and leadership mentoring

4:15 pm Chair’s Closing Remarks

Executive Vice President, General Counsel, Parabilis Medicines

4:20 pm End of the 7th In-House Impact: Biopharma Summit